AbbVie Goes On The Offensive With $10.9 Billion Takeover

The deal bolsters AbbVie's immunology and inflammation pipeline, answering a key investor question about what comes after Skyrizi.

lunedì 22 giugno 2026 New tab

74 words~1 min read

Licensing

09:16 AM ET 06/22/2026

AbbVie (ABBV) announced Monday a $10.9 billion plan to acquire Apogee Therapeutics (APGE), strengthening its immunology pipeline and sending Apogee stock flying. The deal "helps partially solve one of the biggest investor concerns of what drives growth beyond Skyrizi/Rinvoq," RBC Capital Markets analyst Trung Huynh said in a report. Skyrizi and Rinvoq are AbbVie's immunology powerhouses, bringing in a collective…

AbbVie Goes On The Offensive With $10.9 Billion Takeover

AbbVie Goes On The Offensive With $10.9 Billion Takeover

Other newsrooms on this story

Related reading

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition -…

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie to buy Apogee Therapeutics in nearly $11B deal

AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates

Pharma: AbbVie schluckt Biotechfirma Apogee für 10,9 Milliarden Dollar

AbbVie compra Apogee per 10,9 mld $ | MilanoFinanza News

Other newsrooms on this story

Related reading

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition -…

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie to buy Apogee Therapeutics in nearly $11B deal

AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates

Pharma: AbbVie schluckt Biotechfirma Apogee für 10,9 Milliarden Dollar

AbbVie compra Apogee per 10,9 mld $ | MilanoFinanza News